Advanced Search

 

Study ID Status Title Patient Level Data
NAIA1009 Completed Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness. Study Listed on ClinicalStudyDataRequest.com
NAIA2005 Completed A Double-Blind, Randomized Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 in the Treatment of Influenza A and B Infection Study Listed on ClinicalStudyDataRequest.com
NAIA2006 Completed A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 (Zanamivir) Therapy in the Prevention of Progression of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIA2008 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel and Group Study to Investigate the Efficiacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIA2009 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIA2010 Completed Efficacy of Zanamivir (GG167) in Controlling Nursing Home Influenza Outbreaks Study Listed on ClinicalStudyDataRequest.com
NAIA3002 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Study Listed on ClinicalStudyDataRequest.com
NAIA3003 Completed A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks Study Listed on ClinicalStudyDataRequest.com
NAIA3004 Completed A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks. Study Listed on ClinicalStudyDataRequest.com
NAIA3005 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults. Study Listed on ClinicalStudyDataRequest.com
NAIB1001 Completed Pharmacoscintigraphic Evaluation of Lung Deposition of GG167 Inhaled from the Diskhaler and the Free Flow Powder System (FFPS) in Healthy Volunteers Study Listed on ClinicalStudyDataRequest.com
NAIB1002 Completed A Study to Evaluate the Effect of Repeat Doses of GG167 Dry Powder on Pulmonary Function and Bronchial Hyper-Responsiveness in Asthmatic Subjects Study Listed on ClinicalStudyDataRequest.com
NAIB1007 Completed A GG167 Pharmacokinetic Study to Select a Regimen for Prophylaxis Study Listed on ClinicalStudyDataRequest.com
NAIB2005 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Intranasal GG167 in the Treatment of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIB2006 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir in Preventing Progression of Influenza Study Listed on ClinicalStudyDataRequest.com
NAIB2007 Completed Double-Blind, Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Inhaled plus Intranasal GG167 in the Treatment of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIB2008 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIB2009 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIB3001 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. Study Listed on ClinicalStudyDataRequest.com
NAIB3002 Completed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Study Listed on ClinicalStudyDataRequest.com
NKB104846 Terminated A randomized, double-blind, placebo-controlled, crossover study (Part 1) and parallel group design study (Part 2) to evaluate the effects of GW679769 on Current Perception Threshold (CPT) following a single dose and the effect on CPT and symptoms of overactive bladder (OAB) following 28 days of repeat dosing in Patients with Neurogenic Bladder due to Upper Motor Neuron (UMN) Disease
NKB105022 Completed NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder symptoms
NKD10020 Completed A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of GW597599, paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subjects affected by social phobia Study Listed on ClinicalStudyDataRequest.com
NKD20006 Completed An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder Study Listed on ClinicalStudyDataRequest.com
NKE10001 Completed An open-label, repeat-dose, randomized, three-period crossover, parallel-group study to investigate the potential pharmacokinetic interactions between two doses of a new chemical entity (NCE) and ondansetron (OND) and dexamethasone (DEX) when co-administered in healthy adult subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.